Travere Therapeutics Inc.

TVTX

Held by 3 specialist biotech funds

High Convergence

Share on X

Fund Holdings

3 fund convergence

Driehaus Capital Perceptive Advisors Rock Springs Capital

Catalysts

No catalysts tracked.

Activist Filings

SC 13G/ARA Capital Management0.0%May 15, 2023

SC 13G/ARA Capital Management6.2%Feb 14, 2023

SC 13G/A

Position Details

Driehaus CapitalNEWFeb 17, 2026

Shares: 901,404Value: $34.4M

**SIGNAL NOTE: Driehaus Capital Initiates $34.4M Position in Travere Therapeutics** Growth-focused Driehaus is backing Travere's late-stage pipeline, likely positioning for near-term catalysts around IgA nephropathy (PROTECT studies readout expected 2024-2025) and other rare kidney disease programs where the company holds meaningful IP. This 901K share entry into a $1.2B market cap biotech signals conviction in clinical/regulatory inflection points rather than speculative thesis, consistent with Driehaus's growth mandate.

Perceptive AdvisorsNEW

More TVTX Analysis

Insider buy/sell details with names, titles, and amounts
AI-generated context for every signal

Start 7-Day Free Trial — $29/mo

Insider Signals

No insider signals tracked.

Also Held by These Funds

NBIX3 funds AMLX3 funds BSX3 funds XENE3 funds ASND3 funds KYMR3 funds RVMD3 funds RYTM

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Track specialist biotech funds, insider signals, and AI analysis

Start 7-Day Free Trial

Or get the free weekly brief:

AI Signal

AI analyst context — unlock full analysis

# Signal Note: Perceptive Advisors Initiates $163.5M Position in Travere Therapeutics Edelman's new 4.3M share stake in TVTX signals conviction in Travere's clinical pipeline, likely centered on the company's late-stage programs in rare kidney diseases where unmet medical need and limited competition support premium pricing. The $163.5M position size reflects confidence in near-term catalysts, potentially including upcoming Phase 3 readouts or FDA decisions on lead candidates targeting IgA nephropathy and other glomerular diseases. Perceptive's entry merits monitoring given Edelman's track record with clinical-stage assets and Travere's regulatory pathway visibility into 2024-2025.